Pharma BD Deal Intelligence
Allergan paid $2.1B for a single approved aesthetics asset analysts pegged at ~$300M peak — a premium framed by the strategic need to own every game-changing…
Industry observers flagged the rich price relative to Kybella's narrow indication, but acknowledged Allergan's premium-aesthetics commercial machine could…
Kythera shares surged on the $75/share buyout; analysts viewed Kybella as having multi-million dollar potential given submental fullness affects ~67% of…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Allergan acquired Kythera Biopharmaceuticals for approximately $2.1B in cash, gaining Kybella, the first non-surgical injectable treatment for moderate-to-severe submental fullness. Closed October 1, 2015.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Kythera Biopharmaceuticals, Inc. (this deal) | 2015 | $2.1B | 23 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Inamed Corporation | 2005 | $3.2B | 50 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Anterios, Inc. | 2016 | $90M | 19 |
← Browse all deals · How we score deals
More: 2015 deals · Allergan plc deals · Other deals